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In the Hematopoietic Stem Cell Transplantation 2008 Education Supplement to the January 2008 issue of
Biology of Blood and Marrow Transplantation (Volume 14, Number 1, Supplement 1, pp1-170), the financial dis-
closure statements of the authors were not included. The authors’ financial disclosure statements are listed
below.
Associate Editors: Drs. Appelbaum, Cooke, Davies, DiPersio, Laport, and Ritz have nothing to disclose.
The 2008 Education Supplement on Hematopoietic Stem Cell Transplantation. 2008;14(Suppl 1):1.
Dr. van den Brink has nothing to disclose.
The graft-versus-leukemia effect - breaking the black box open. 2008;14(Suppl 1):2-3. Dr. Riddell has
nothing to disclose.
GVL against murine chronic phase and blast phase CML. 2008;14(Suppl 1):4. Dr. Shlomchik has nothing
to disclose.
Engineering GVL through T cell gene transfer. 2008;14(Suppl 1):5. Dr. Jensen has nothing to disclose.
Amyloidosis 2008 BMT Tandem Meetings (February 13-17, San Diego). 2008;14(Suppl 1):6-11.
Drs. Dispenzieri, Merlini, and Comenzo have nothing to disclose.
Cancer stem cells in hematopoietic malignancies. 2008;14(Suppl 1):12-16. Drs. Jones and Armstrong have
nothing to disclose.
Memory T cells. 2008;14(Suppl 1):17-22. Drs. Chao, Anderson, Zheng, Taylor, Matte-Martone, McNiff,
Jain, Demetris, Panoskaltsis,-Mortari, Ager, Blazar, M. Shlomchik, W. Shlomchik, and Chen have nothing to
disclose.
The contribution of endothelial activation and injury to end-organ toxicity following allogeneic hemato-
poietic stem cell transplantation. 2008;14(Suppl 1):23-32. Dr. Cooke received clinical trial and research sup-
port from Amgen Inc. Drs. Jannin and Ho have nothing to disclose.
Immunotherapy for pediatric cancer. 2008;14(Suppl 1):33-43. Dr. Cooper occasionally receives honorar-
ium for providing teaching for Schering-Plough. Drs. Grupp, Verneris, and Sondel have nothing to disclose.
Alternative allogeneic donor sources for transplantation for childhood diseases: Unrelated cord blood and
haploidentical family donors. 2008;14(Suppl 1):44-53. Drs. Cairo, Rocha, Gluckman, Hale, andWagner have
nothing to disclose.
Vaccination of children following allogeneic stem cell transplantation. 2008;14(Suppl 1):54-58. Dr. Small
has nothing to disclose. Dr. Small’s full credentials were not listed in the article. His full credentials are: Trudy
N. Small, MD, Associate Member, Department of Pediatrics and Clinical Laboratory Medicine, Pediatric
Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY.
Cellular immune reconstitution after haploidentical transplantation in children. 2008;14(Suppl 1):59-65.
Drs. Handgretinger, Chen, Pfeiffer, Schumm, Mueller, Feuchtinger, Hale and Lang have nothing to disclose.
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1318 Biol Blood Marrow Transplant 14:1317-1318, 2008ErratumImmune reconstitution in children after unrelated cord blood transplantation. 2008;14(Suppl 1):66-72.
Drs. Szabolcs and Niedzwiecki have nothing to disclose.
Hematopoietic stem cell transplantation for severe combined immunodeficiency diseases. 2008;14(Suppl
1):73-80. Drs. Neven, Fischer, Cavazanna-Calvo, Cowan, and Puck have nothing to disclose.
Oral and dental late effects after pediatric stem cell transplantation. 2008;14(Suppl 1):81-83. Dr. Dahllof
has nothing to disclose.
Chronic kidney disease after pediatric hematopoietic cell transplant. 2008;14(Suppl 1):84-87. Dr. Hingorani
has nothing to disclose.
Late effects followinghematopoietic cell transplantation for children. 2008;14(Suppl 1):88-93.Drs.Dahllo¨f,
Hingorani, and Sanders have nothing to disclose.
Clinical strategies to enhance posttransplant immune reconstitution. 2008;14(Suppl 1):94-99. Drs. Bern-
stein, Boyd, van den Brink, Delaney, Dallas, Heimfeld, Varnum-Finney, Goldberg, Zakrzewski, Sutherland,
Heng, Gray, Fletcher, Seach, and Chidgey have nothing to disclose.
Controversies in lymphoma: The role of hematopoietic cell transplantation for mantle cell lymphoma and
peripheral T cell lymphoma. 2008;14(Suppl 1):100-107. Drs. Laport and Dreger have nothing to disclose.
Diffuse large B cell lymphoma: From gene expression profiling to prediction of outcome. 2008;14(Suppl
1):108-111. Dr. Lossos has nothing to disclose.
Principles and tools for selection of umbilical cord blood and unrelated adult donor grafts. 2008;14(Suppl
1):112-119. Drs. Confer, Lee and Kamani have nothing to disclose.
Human polymorphism and variable outcomes of cancer chemotherapy and transplantation. 2008;14(Suppl
1):120-128. Dr. Davies, Dickinson, and Miller have nothing to disclose.
Mouse models of bone marrow transplantation. 2008;14(Suppl 1):129-135. Drs. Reddy, Negrin, and Hill
have nothing to disclose.
T cell therapy in allogeneic stem cell transplantation. 2008;14(Suppl 1):136-141. Drs. Falkenburg, Barrett,
and Heslop have nothing to disclose.
Chronic graft-versus-host disease: How can we release prometheus? 2008;14(Suppl 1):142-150.
Drs. Teshima, Wynn, Soiffer, Matsuoka, and Martin have nothing to disclose.
Human stem cells for tissue repair. 2008;14(Suppl 1):151-153. Drs. Nolta, Wirthlin, Hess, and Zhou have
nothing to disclose.
Indications for hematopoietic cell transplantation in acute leukemia. 2008;14(Suppl 1):154-164.
Drs. Appelbaum, Davies, and Rowe have nothing to disclose.
Graft failure after allogeneic hematopoietic cell transplantation. 2008;14(Suppl 1):165-170. Drs. Ringden,
Mattsson, and Storb have nothing to disclose.
